Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comparator choices in pharmacoepidemiology studies of Alzheimer’s disease

Matters Arising to this article was published on 22 May 2023

The Original Article was published on 06 December 2021

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Fang, J. et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nat. Aging (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sendor, R. & Stürmer, T. Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. Pharmacoepidemiol. Drug Saf. 31, 261–269 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  3. D’Arcy, M., Stürmer, T. & Lund, J. L. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr. Epidemiol. Rep. 5, 272–283 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lund, J. L., Richardson, D. B. & Stürmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221–228 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kramer, M. S., Lane, D. A. & Hutchinson, T. A. Analgesic use, blood dyscrasias, and case-control pharmacoepidemiology. A critique of the International Agranulocytosis and Aplastic Anemia Study. J. Chronic Dis. 40, 1073–1085 (1987).

    Article  CAS  PubMed  Google Scholar 

  6. Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Humbert, M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61, 2200879 (2023).

    Article  PubMed  Google Scholar 

  8. Desai, R. J. et al. Targeting abnormal metabolism in Alzheimer’s disease: the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study. Alzheimers Dement. 6, e12095 (2020).

    Google Scholar 

  9. Barlow, A., Barlow, B., Koyfman, A., Long, B. & Bissell, B. Pulmonary arterial hypertension in the emergency department: a focus on medication management. Am. J. Emerg. Med. 47, 101–108 (2021).

    Article  PubMed  Google Scholar 

  10. Mulhall, J. P., Chopra, I., Patel, D., Hassan, T. A. & Tang, W. Y. Phosphodiesterase type-5 inhibitor prescription patterns in the United States among men with erectile dysfunction: an update. J. Sex. Med. 17, 941–948 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schneeweiss, S. et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med. Care 45, S131–S142 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pottegård, A. et al. Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. Pharmacoepidemiol. Drug Saf. 31, 257–259 (2022).

    Article  PubMed  Google Scholar 

Download references


J.C.K. has previously received funding as a graduate research assistant from Merck & Co., Inc as well as GSK plc. T.S. receives investigator-initiated research funding and support as principal investigator (R01AG056479) from the National Institute on Aging, and as co-investigator (R01HL118255, R01MD011680), National Institutes of Health. He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, Boehringer Ingelheim), from pharmaceutical companies (Novo Nordisk) and from a generous contribution from Dr Nancy A. Dreyer to the Department of Epidemiology, University of North Carolina at Chapel Hill.

Author information

Authors and Affiliations



Q.L.H., J.C.K. and T.S. contributed to the development, drafting, reviewing and revising of this paper. Q.L.H., J.C.K. and T.S. approved the final version.

Corresponding author

Correspondence to Qoua L. Her.

Ethics declarations

Competing interests

Q.L.H., J.C.K. and T.S. declare no competing interests. T.S. does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche and Novo Nordisk.

Peer review

Peer review information

Nature Aging thanks Emre Guney, Heather Allore, Jennifer Weuve and Kevin Wing for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Her, Q.L., Kahrs, J.C. & Stürmer, T. Comparator choices in pharmacoepidemiology studies of Alzheimer’s disease. Nat Aging 3, 791–792 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing